1
|
Ren H, Hu Y, Xie T, Jin C, Hu Y, Yang B. Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer. Oncol Lett 2019; 18:4167-4175. [PMID: 31516615 PMCID: PMC6732996 DOI: 10.3892/ol.2019.10762] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Accepted: 07/01/2019] [Indexed: 12/26/2022] Open
Abstract
Changes of epidermal growth factor receptor (EGFR) and cytokeratin fragment antigen 21-1 (CYFRA21-1) in patients with advanced non-small cell lung cancer (NSCLC) before and after gefitinib treatment were observed to explore the significance of such changes. A total of 175 patients with advanced NSCLC who were admitted to Hubei Cancer Hospital from July 2012 to October 2015 were collected and divided into two groups: the control group (85 patients who received conventional chemotherapy) and the experimental group (90 patients treated with gefitinib combined with chemotherapy). The serum expression levels of EGFR and CYFRA21-1 were detected by enzyme-linked immunosorbent assay (ELISA). The therapeutic efficacy and 3-year survival of the two groups were compared, and the factors affecting the survival of the patients were analyzed. The total effective rate and local effective rate of the experimental group were significantly higher than those of the control group (P<0.05). Before treatment, no significant difference was detected in the levels of EGFR and CYFRA21-1 between the two groups (P>0.05). After treatment, the expression levels of EGFR and CYFRA21-1 in the two groups were significantly lower than those before treatment (P<0.05). According to the 3-year survival rate, the experimental group was divided into the survival group and the non-survival group. Single factor analysis was performed on the general data, showing that the influencing factors of the survival include the KPS score, smoking history, number of lesions, pathological stage, EGFR, and CYFRA21-1. Gefitinib can bring significantly improved therapeutic efficacy, lower expression levels of EGFR and CYFRA21-1, and longer survival time for patients with advanced NSCLC. Indicators including confirmed smoking history, a KPS score less than or equal to 60 points, multiple lesions, pathological stage IV, high expression of EGFR and CYFRA21-1, are important factors affecting the survival of patient with advanced NSCLC.
Collapse
Affiliation(s)
- Hui Ren
- Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, Hubei 430079, P.R. China
| | - Yang Hu
- Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, Hubei 430079, P.R. China
| | - Tao Xie
- Department of Head and Neck Radiotherapy, Hubei Cancer Hospital, Wuhan, Hubei 430079, P.R. China
| | - Caibao Jin
- Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, Hubei 430079, P.R. China
| | - Yanping Hu
- Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, Hubei 430079, P.R. China
| | - Bin Yang
- Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, Hubei 430079, P.R. China
| |
Collapse
|
2
|
Liu Y, Xun XH, Yi JM, Xiang Y, Hua J. Discovery of lung squamous carcinoma biomarkers by profiling the plasma peptide with LC/MS/MS. CHINESE CHEM LETT 2017. [DOI: 10.1016/j.cclet.2016.11.026] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
3
|
Zhao T, Jin Y, Mao G, Wei Y, Wu G, Ye X, Zhou Y, Yuan G, Gao L, Hong Y, Chen Y, Hong C, Zhou H, Su D, Qin Z, Lu L. CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study. Medicine (Baltimore) 2016; 95:e5748. [PMID: 28033287 PMCID: PMC5207583 DOI: 10.1097/md.0000000000005748] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Serum cytokeratin 19 fragment (CYFRA21-1) has been found to be a useful prognostic marker in lung cancer. Previous studies have revealed that change in CYFRA21-1 synchronously predicted therapeutic effectiveness in advanced nonsmall cell lung cancer (NSCLC) after the second cycle of chemotherapy. The objective of this study was to investigate the early predictive value of percentage change in serum CYFRA21-1 from pretreatment to completion of the first cycle of chemotherapy for chemotherapeutic effectiveness in advanced NSCLC patients.Ninety-seven advanced NSCLC patients with elevated serum CYFRA21-1 level (≥3.8 μg/L), who received 2 platinum-containing drugs, were included in this retrospective study. Serum CYFRA21-1 had been assayed before and after the first cycle of chemotherapy. To evaluate the effectiveness of chemotherapy, patients were allocated to disease control (DC) and progressive disease groups. The percentage changes of serum CYFRA21-1 concentration before and after first-cycle chemotherapy that occurred in each group were evaluated for their ability to predict achievement of radiologic DC, that is, to predict therapeutic effectiveness.The percentage change of serum CYFRA21-1 and the prevalence of ≥5% weight loss were higher in patients with progressive disease than in those with DC. The differences in other clinical and pathological variables including age, sex, Eastern Cooperative Oncology Group (ECOG) performance status, cigarette smoking, histological type, gross type, clinical stage, and chemotherapy regimens of the 2 groups were not significant. Both multiple generalized linear model analysis and linear trend tests indicated that the percentage change of serum CYFRA21-1 concentration was independently and negatively linked to the effectiveness of chemotherapy for NSCLC (P < 0.01). The area under the receiver-operating characteristic curve of the percentage change in prediction of DC was 0.84 and the optimal cut-off value was17.5% (P < 0.001).The percentage change of serum CYFRA21-1 after completing the first cycle of chemotherapy was predictive of treatment effects and might be helpful in making early decisions to change chemotherapy regimens in patients with advanced NSCLC.
Collapse
Affiliation(s)
- Tongwei Zhao
- Department of Medical Oncology, Zhejiang Provincial People's Hospital
| | - Ying Jin
- Department of Medical Oncology, Zhejiang Cancer Hospital
| | - Guangyun Mao
- Department of Preventive Medicine, School of Environmental Science & Public Health, Wenzhou Medical University
- Center on Clinical & Epidemiological Eye Research, the Affiliated Eye Hospital of Wenzhou Medical University
| | - Yaping Wei
- Department of Preventive Medicine, School of Environmental Science & Public Health, Wenzhou Medical University
| | - Guoqing Wu
- Department of Medical Oncology, Zhejiang Provincial People's Hospital
| | - Xiao Ye
- Department of Endocrinology, Zhejiang Provincial People's Hospital
| | - Yonglie Zhou
- Clinical Laboratory Center, Zhejiang Provincial People's Hospital, Zhejiang, P.R. China
| | - Guorong Yuan
- Department of Medical Oncology, Zhejiang Provincial People's Hospital
| | - Liang Gao
- Department of Medical Oncology, Zhejiang Provincial People's Hospital
| | - Yupeng Hong
- Department of Medical Oncology, Zhejiang Provincial People's Hospital
| | - Yun Chen
- Department of Medical Oncology, Zhejiang Provincial People's Hospital
| | - Chaojin Hong
- Department of Medical Oncology, Zhejiang Provincial People's Hospital
| | - Hongying Zhou
- Department of Medical Oncology, Zhejiang Provincial People's Hospital
| | - Dan Su
- Department of Medical Oncology, Zhejiang Provincial People's Hospital
| | - Zhiquan Qin
- Department of Medical Oncology, Zhejiang Provincial People's Hospital
| | - Liqin Lu
- Department of Medical Oncology, Zhejiang Provincial People's Hospital
| |
Collapse
|
4
|
Sun L, Chen Y, Su Q, Tang X, Liang Y, Che G, Luo F. Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer. Med Sci Monit 2016; 22:647-55. [PMID: 26918265 PMCID: PMC4771099 DOI: 10.12659/msm.897330] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Background MicroRNA (miRNA) is a small, non-coding RNA molecule which plays a role in the carcinogenesis and progression of cancers. Abnormal expression of miRNA in plasma has been found in some patients with malignant tumors. Material/Methods This study was conducted to investigate the expression of miRNA-30a in plasma of patients with non-small cell lung cancer (NSCLC). The plasma miRNA-30a in 87 patients with NSCLC, 20 patients with benign lung diseases, and 76 healthy subjects were measured by real-time PCR. The diagnostic value of miRNA-30a in NSCLC was evaluated via the ROC curve method. Results Plasma miRNA-30a level was significantly higher in the NSCLC group compared with benign control and healthy control groups (P<0.01). No statistically significant difference was found in the expression level of miRNA-30a among various clinical pathologic features in NSCLC. ROC curve analysis showed that the specificity and sensitivity cut-off points were at 61.0% and 84.3% for NSCLC. The specificity and sensitivity values were 54.9% and 94.4%, respectively, in the analysis based on in-patients only. Conclusions All these results suggest that plasma miRNA-30a measurement may be a novel and noninvasive method for NSCLC preliminary screening and differential diagnosis.
Collapse
Affiliation(s)
- Ling Sun
- Laboratory of Cardiovascular Disease, Research Center of Regeneration Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China (mainland)
| | - Yifan Chen
- Department of Pulmonary Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China (mainland)
| | - Qiaoli Su
- Department of Family Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China (mainland)
| | - Xiaoju Tang
- Laboratory of Cardiovascular Disease, Research Center of Regeneration Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China (mainland)
| | - Yasha Liang
- Department of Family Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China (mainland)
| | - Guowei Che
- Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China (mainland)
| | - Fengming Luo
- Department of Family Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China (mainland)
| |
Collapse
|
5
|
Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer. DISEASE MARKERS 2016; 2016:3823121. [PMID: 26880855 PMCID: PMC4737022 DOI: 10.1155/2016/3823121] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/03/2015] [Revised: 12/12/2015] [Accepted: 12/15/2015] [Indexed: 11/18/2022]
Abstract
OBJECTIVE To compare the clinical value of serum microRNA21 (miR21) and other tumor markers in early diagnosis of non-small cell lung cancer (NSCLC). METHODS Serums carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), and miR21 were detected in 50 NSCLC cases and 60 healthy control individuals. RESULTS Average serums miR21, CEA, NSE, and CYFRA21-1 levels were significantly higher in the case group than in control group (P < 0.01). Analysis of areas under the receiver operating characteristic (ROC) curve (AUC) revealed that CEA had the highest diagnostic efficiency for NSCLC. Serums miR21 and CYFRA21-1 levels were significantly lower at TNM stages I-II than stages III-IV (P < 0.05). Further, logistic multivariate regression analysis showed that the incidence of early NSCLC (TNM stages I-II) was correlated with serums CYFRA21-1 (OR = 1.076) and miR21 (OR = 2.473) levels (P < 0.05). By AUC analysis, miR21 had the highest diagnostic efficiency for early NSCLC, and single or combined detection of serums CYFRA21-1 and miR21 levels showed improved diagnostic efficiency for joint detection of both markers. CONCLUSIONS Serum miR21 could serve as an important marker for auxiliary diagnosis of early NSCLC, while joint detection of serums miR21 and CYFRA21-1 levels could improve diagnostic efficiency.
Collapse
|
6
|
Pang L, Wang J, Jiang Y, Chen L. Decreased levels of serum cytokeratin 19 fragment CYFRA 21-1 predict objective response to chemotherapy in patients with non-small cell lung cancer. Exp Ther Med 2013; 6:355-360. [PMID: 24137188 PMCID: PMC3786728 DOI: 10.3892/etm.2013.1171] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Accepted: 06/14/2013] [Indexed: 11/28/2022] Open
Abstract
Diagnostic tools capable of predicting early responses to chemotherapy are required to improve the individual management of cancer patients. The present study aimed to evaluate the prognostic significance of the serum tumor markers CYFRA 21-1, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), carbohydrate antigen (CA) 125, and CA 19-9 for predicting responses to different chemotherapy regimens in patients with non-small cell lung cancer (NSCLC). A total of 276 patients with postoperative stage I–IV NSCLC were retrospectively reviewed. The five tumor markers were measured before and after at least two cycles of chemotherapy using an electrochemiluminescent assay. Multivariate analysis revealed that performance status, age, postoperative stage and surgery were significantly associated with the response to chemotherapy. High baseline CYFRA 21-1 and CA 19-9 levels were associated with poor effectiveness of chemotherapy. Significant reductions in CYFRA 21-1 levels were associated with a positive response to various chemotherapy regimens. CEA, CA 125 and CA 19-9 expression was only associated with a positive response in patients receiving paclitaxel, docetaxel, pemetrexed and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). NSE expression was only associated with a positive response to gemcitabine. Receiver operating characteristic (ROC) curve analysis indicated that CYFRA 21-1 is the most sensitive of the tumor markers in predicting the response to chemotherapy. Serum CYFRA 21-1 is a useful surrogate marker for predicting the response to different chemotherapy regimens used to treat NSCLC and is a more sensitive marker than CEA, CA125, CA19-9 and NSE.
Collapse
Affiliation(s)
- Li Pang
- Department of Respiratory Medicine, Chinese PLA General Hospital, Beijing 100853
| | | | | | | |
Collapse
|
7
|
Heuvers ME, Aerts JG, Cornelissen R, Groen H, Hoogsteden HC, Hegmans JP. Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer 2012; 12:580. [PMID: 23217146 PMCID: PMC3533940 DOI: 10.1186/1471-2407-12-580] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2012] [Accepted: 11/15/2012] [Indexed: 12/16/2022] Open
Abstract
Cancer research has devoted most of its energy over the past decades on unraveling the control mechanisms within tumor cells that govern its behavior. From this we know that the onset of cancer is the result of cumulative genetic mutations and epigenetic alterations in tumor cells leading to an unregulated cell cycle, unlimited replicative potential and the possibility for tissue invasion and metastasis. Until recently it was often thought that tumors are more or less undetected or tolerated by the patient’s immune system causing the neoplastic cells to divide and spread without resistance. However, it is without any doubt that the tumor environment contains a wide variety of recruited host immune cells. These tumor infiltrating immune cells influence anti-tumor responses in opposing ways and emerges as a critical regulator of tumor growth. Here we provide a summary of the relevant immunological cell types and their complex and dynamic roles within an established tumor microenvironment. For this, we focus on both the systemic compartment as well as the local presence within the tumor microenvironment of late-stage non-small cell lung cancer (NSCLC), admitting that this multifaceted cellular composition will be different from earlier stages of the disease, between NSCLC patients. Understanding the paradoxical role that the immune system plays in cancer and increasing options for their modulation may alter the odds in favor of a more effective anti-tumor immune response. We predict that the future standard of care of lung cancer will involve patient-tailor-made combination therapies that associate (traditional) chemotherapeutic drugs and biologicals with immune modulating agents and in this way complement the therapeutic armamentarium for this disease.
Collapse
Affiliation(s)
- Marlies E Heuvers
- Department of Pulmonary Medicine, Erasmus Medical Center, Postbox 2040, 3000 CA, Rotterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|